Bharat Biotech to add ICMR as co-owner of Covid-19 vaccine patent, also state reasons

Posted on

Bharat Biotech signed an agreement with ICMR in April 2020 for joint development of a Covid-19 vaccine.


Bharat Biotech (BBIL) has said it will add ICMR as a co-owner of the Covid-19 vaccine patent. Its process has started. Explaining the reason for co-owning ICMR, Bharat Biotech said that at the time of Covid, its full focus was on making the vaccine available as soon as possible. He had to face many challenges in making the Covid vaccine. Companies around the world were also rushing to develop their vaccines and file appropriate patents before any data was published in journals.

It was in these circumstances that Bharat Biotech’s Covid vaccine application was filed and since a copy of the BBIL-ICMR agreement was not available, ICMR was not included in the original application as it was a confidential document. Although it was completely unintentional, such mistakes are not uncommon for the Patent Office, so the patent law provides provisions for correcting such mistakes.

India Biotech holds ICMR in high esteem and is grateful for their continuous support on various projects, so upon learning of this inadvertent error, BBIL has already initiated the process by including ICMR as a co-owner of the patent applications for the Covid-19 vaccine. .

Necessary legal documents for this are being prepared and BBIL will file those documents with the Patent Office as soon as they are prepared and signed. These actions are in accordance with the Memorandum of Understanding (MoU) signed between ICMR-NIV Pune and BBIL in April 2020 for the joint development of a COVID-19 vaccine.

Leave a Reply

Your email address will not be published. Required fields are marked *